XFOR
Price:
$4.125
Market Cap:
$47.06M
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporati...[Read more]
Industry
Biotechnology
IPO Date
2017-11-16
Stock Exchange
NASDAQ
Ticker
XFOR
According to X4 Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.21. This represents a change of -123.90% compared to the average of 9.25 of the last 4 quarters.
The mean historical PE Ratio of X4 Pharmaceuticals, Inc. over the last ten years is -1.49. The current -2.21 PE Ratio has changed 14.72% with respect to the historical average. Over the past ten years (40 quarters), XFOR's PE Ratio was at its highest in in the March 2025 quarter at 42.99. The PE Ratio was at its lowest in in the March 2016 quarter at -71.63.
Average
-1.49
Median
-1.46
Minimum
-3.94
Maximum
-0.03
Discovering the peaks and valleys of X4 Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 7.21%
Maximum Annual PE Ratio = -0.03
Minimum Annual Increase = -91.10%
Minimum Annual PE Ratio = -3.94
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -2.14 | -45.77% |
| 2024 | -3.94 | 167.22% |
| 2023 | -1.47 | 119.34% |
| 2022 | -0.67 | 1.09% |
| 2021 | -0.66 | -68.00% |
| 2020 | -2.08 | -11.06% |
| 2019 | -2.34 | 7.21% |
| 2018 | -0.03 | -75.29% |
| 2017 | -0.13 | -91.10% |
| 2016 | -1.45 | -27.14% |
The current PE Ratio of X4 Pharmaceuticals, Inc. (XFOR) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.52
5-year avg
-1.78
10-year avg
-1.49
X4 Pharmaceuticals, Inc.’s PE Ratio is greater than Aligos Therapeutics, Inc. (-2.58), less than Karyopharm Therapeutics Inc. (-0.79), less than FibroGen, Inc. (0.16), less than Mersana Therapeutics, Inc. (-2.07), less than Kezar Life Sciences, Inc. (-0.95), less than Senti Biosciences, Inc. (-0.33), less than INmune Bio, Inc. (-0.79), less than Skye Bioscience, Inc. (-0.60), less than OnKure Therapeutics, Inc. (-1.17), less than Tempest Therapeutics, Inc. (-0.31),
| Company | PE Ratio | Market cap |
|---|---|---|
| -2.58 | $37.20M | |
| -0.79 | $73.46M | |
| 0.16 | $36.69M | |
| -2.07 | $145.36M | |
| -0.95 | $53.63M | |
| -0.33 | $23.98M | |
| -0.79 | $36.47M | |
| -0.60 | $29.86M | |
| -1.17 | $70.52M | |
| -0.31 | $8.73M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like X4 Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like X4 Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is X4 Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for X4 Pharmaceuticals, Inc. (XFOR)?
What is the highest PE Ratio for X4 Pharmaceuticals, Inc. (XFOR)?
What is the 3-year average PE Ratio for X4 Pharmaceuticals, Inc. (XFOR)?
What is the 5-year average PE Ratio for X4 Pharmaceuticals, Inc. (XFOR)?
How does the current PE Ratio for X4 Pharmaceuticals, Inc. (XFOR) compare to its historical average?